These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 31963413)

  • 1. Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges.
    Kunimasa K; Goto T
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer.
    Anagnostou VK; Brahmer JR
    Clin Cancer Res; 2015 Mar; 21(5):976-84. PubMed ID: 25733707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy.
    Vesely MD; Schreiber RD
    Ann N Y Acad Sci; 2013 May; 1284(1):1-5. PubMed ID: 23651186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
    Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E
    Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
    Yang J; Chen J; Wei J; Liu X; Cho WC
    Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What lies within: novel strategies in immunotherapy for non-small cell lung cancer.
    Forde PM; Reiss KA; Zeidan AM; Brahmer JR
    Oncologist; 2013; 18(11):1203-13. PubMed ID: 24105749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. OMIC signatures to understand cancer immunosurveillance and immunoediting: Melanoma and immune cells interplay in immunotherapy.
    León-Letelier RA; Bonifaz LC; Fuentes-Pananá EM
    J Leukoc Biol; 2019 May; 105(5):915-933. PubMed ID: 30698862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
    Yoneda K; Imanishi N; Ichiki Y; Tanaka F
    J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The next generation of immunotherapy: keeping lung cancer in check.
    Somasundaram A; Burns TF
    J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for non-small-cell lung cancer.
    Thomas A; Jakopovic M
    Expert Opin Biol Ther; 2014 Aug; 14(8):1061-4. PubMed ID: 24878420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer immunoediting: from immunosurveillance to tumor escape.
    Dunn GP; Bruce AT; Ikeda H; Old LJ; Schreiber RD
    Nat Immunol; 2002 Nov; 3(11):991-8. PubMed ID: 12407406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?
    Qiao M; Jiang T; Ren S; Zhou C
    Clin Lung Cancer; 2018 Jan; 19(1):1-11. PubMed ID: 28716463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in the treatment of non-small cell lung cancer.
    Sundar R; Soong R; Cho BC; Brahmer JR; Soo RA
    Lung Cancer; 2014 Aug; 85(2):101-9. PubMed ID: 24880938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural innate and adaptive immunity to cancer.
    Vesely MD; Kershaw MH; Schreiber RD; Smyth MJ
    Annu Rev Immunol; 2011; 29():235-71. PubMed ID: 21219185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice.
    Passiglia F; Commendatore O; Vitali M; Conca R
    Future Oncol; 2018 Jun; 14(13s):41-60. PubMed ID: 29989452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Advances of RNA m
    Ma S; Barr T; Yu J
    Cancer Treat Res; 2023; 190():49-94. PubMed ID: 38112999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging biomarkers for immune checkpoint inhibition in lung cancer.
    Cyriac G; Gandhi L
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):269-277. PubMed ID: 29782924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.